Najah Sampson is appointed new President of Pfizer Canada
by CM Staff
In her previous role, she was responsible for ensuring global strategy development and implementation for a portfolio of brands and pipeline medicines.
KIRKLAND — Najah Sampson has been named President of Pfizer Canada ULC, effective May 16, 2022.
Ms. Sampson will be succeeding Cole Pinnow, who has held the position since January 2020.
Mr. Pinnow has been appointed to a position within Pfizer’s global Oncology organization.
Prior to this role, Ms. Sampson was Vice President, Global Genitourinary Franchise Lead for Pfizer Oncology. She was responsible for ensuring global strategy development and implementation for a portfolio of brands and pipeline medicines in prostate, bladder and kidney cancers and the Oncology biosimilar portfolio.
In her career at Pfizer, Ms. Sampson has held commercial leadership positions at various levels in the organization. Ms. Sampson served as Vice President and Chief of Staff to Pfizer’s Chairman and CEO, overseeing operations to advance enterprise priorities, supporting the Executive Leadership Team and Board of Directors, and coordinating with leaders across the organization to enable a strong corporate culture. Ms. Sampson began her career with Pfizer in the US organization managing a portfolio of quality improvement programs and enabling engagement strategies for managed care and institutional customers.